NCT06275555 Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
| NCT ID | NCT06275555 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xiaotong Hou |
| Condition | Extracorporeal Membrane Oxygenation Complication |
| Study Type | INTERVENTIONAL |
| Enrollment | 154 participants |
| Start Date | 2024-06-03 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 154 participants in total. It began in 2024-06-03 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years old 2. Accept VA-ECMO or VV-ECMO 3. the ECMO team believes that systemic anticoagulation is necessary and that APTT should be maintained at 40-60s. 4. sign the informed consent form Exclusion Criteria: 1. previous history of allergy to heparin or bivalirudin 2. previous diagnosis of heparin-induced thrombocytopenia. 3. the pre-random ECMO assistance time is more than 48 hours. 4. pregnant female 5. have participated in this study before. 6. the researchers believe that there are other factors that are not suitable to participate in this study.
Contact & Investigator
Liangshan Wang, MD
STUDY CHAIR
Beijing Anzhen Hospital
Frequently Asked Questions
Who can join the NCT06275555 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Extracorporeal Membrane Oxygenation Complication. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06275555 currently recruiting?
Yes, NCT06275555 is actively recruiting participants. Contact the research team at xt.hou@ccmu.edu.cn for enrollment information.
Where is the NCT06275555 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06275555 clinical trial?
NCT06275555 is sponsored by Xiaotong Hou. The principal investigator is Liangshan Wang, MD at Beijing Anzhen Hospital. The trial plans to enroll 154 participants.